Targeted delivery of antisense oligonucleotides to pancreatic β-cells

被引：121

作者：

Ammala, C. ^{[1
]}

Drury, W. J., III ^{[1
]}

Knerr, L. ^{[1
]}

Ahlstedt, I ^{[1
]}

Stillemark-Billton, P. ^{[1
]}

Wennberg-Huldt, C. ^{[1
]}

Andersson, E-M ^{[1
]}

Valeur, E. ^{[1
]}

Jansson-Lofmark, R. ^{[1
]}

Janzen, D. ^{[1
]}

Sundstrom, L. ^{[2
]}

Meuller, J. ^{[2
]}

Claesson, J. ^{[2
]}

Andersson, P. ^{[3
]}

Johansson, C. ^{[3
]}

Lee, R. G. ^{[4
]}

Prakash, T. P. ^{[4
]}

Seth, P. P. ^{[4
]}

Monia, B. P. ^{[4
]}

Andersson, S. ^{[1
]}

机构：

[1] AstraZeneca, IMED Biotech Unit, Cardiovasc Renal & Metab Dis, Gothenburg, Sweden

[2] AstraZeneca, IMED Biotech Unit, Discovery Sci, Gothenburg, Sweden

[3] AstraZeneca, IMED Biotech Unit, Drug Safety & Metab, Gothenburg, Sweden

[4] Ionis Pharmaceut, 2855 Gazelle Court, Carlsbad, CA 92010 USA

来源：

SCIENCE ADVANCES | 2018年 / 4卷 / 10期

关键词：

PEPTIDE-1; RECEPTOR; TRAFFICKING; GLP-1; HEPATOCYTES; TYPE-2; ENDOCYTOSIS; THERAPIES; LIVER; MICE;

D O I：

10.1126/sciadv.aat3386

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Antisense oligonucleotide (ASO) silencing of the expression of disease-associated genes is an attractive novel therapeutic approach, but treatments are limited by the ability to deliver ASOs to cells and tissues. Following systemic administration, ASOs preferentially accumulate in liver and kidney. Among the cell types refractory to ASO uptake is the pancreatic insulin-secreting beta-cell. Here, we show that conjugation of ASOs to a ligand of the glucagon-like peptide-1 receptor (GLP1R) can productively deliver ASO cargo to pancreatic beta-cells both in vitro and in vivo. Ligand-conjugated ASOs silenced target genes in pancreatic islets at doses that did not affect target gene expression in liver or other tissues, indicating enhanced tissue and cell type specificity. This finding has potential to broaden the use of ASO technology, opening up novel therapeutic opportunities, and presents an innovative approach for targeted delivery of ASOs to additional cell types.

引用

页数：11

共 50 条

[31] A two step model aimed at delivering antisense oligonucleotides in targeted cells
Toth, J
Boszormenyi, I
Majer, ZS
Laczko, I
Malvy, C
Hollosi, M
Bertrand, JR
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 293 (01) : 18 - 22
[32] Targeted nanoparticles enhanced flow electroporation of antisense oligonucleotides in leukemia cells
Wang, Shengnian
Zhang, Xulang
Yu, Bo
Lee, Robert J.
Lee, L. James
BIOSENSORS & BIOELECTRONICS, 2010, 26 (02): : 778 - 783
[33] The cellular delivery of antisense oligonucleotides and ribozymes
Hughes, MD
Hussain, M
Nawaz, Q
Sayyed, P
Akhtar, S
DRUG DISCOVERY TODAY, 2001, 6 (06) : 303 - 315
[34] In vitro transport and delivery of antisense oligonucleotides
Hughes, J
Astriab, A
Yoo, H
Alahari, S
Liang, E
Sergueev, D
Shaw, BR
Juliano, RL
ANTISENSE TECHNOLOGY, PT A: GENERAL METHODS, METHODS OF DELIVERY, AND RNA STUDIES, 2000, 313 : 342 - 358
[35] Polymersome delivery of siRNA and antisense oligonucleotides
Kim, Younghoon
Tewari, Manorama
Pajerowski, J. David
Cai, Shenshen
Sen, Shamik
Williams, Jason
Sirsi, Shashank
Lutz, Gordon
Discher, Dennis E.
JOURNAL OF CONTROLLED RELEASE, 2009, 134 (02) : 132 - 140
[36] Oral delivery of antisense oligonucleotides in man
Tillman, Lloyd G.
Geary, Richard S.
Hardee, Gregory E.
JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 97 (01) : 225 - 236
[37] Topical and transdermal delivery of antisense oligonucleotides
Brand, RM
CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2001, 3 (03) : 244 - 248
[38] Oral delivery of siRNA and antisense oligonucleotides
Akhtar, Saghir
JOURNAL OF DRUG TARGETING, 2009, 17 (07) : 491 - 495
[39] Polymersome delivery of siRNA and antisense oligonucleotides
Discher, Dennis E.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237
[40] Attempt for liver-targeted delivery of antisense oligonucleotides by cholesterol modification and oral administration
Okamoto, Y
Nakano, H
HEPATOLOGY RESEARCH, 1999, 13 (03) : 252 - 258

← 1 2 3 4 5 →